STAT+: A year after petition, NIH reviews request to lower cancer drug’s cost by sidestepping patents
One year after being asked to widen access to a pricey cancer treatment by using…
Category: Pharmaceuticals
STAT+: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care
In the fight to command the growing market for telehealth, Thirty Madison is staking out…
STAT+: AAM’s Dan Leonard, president of generic drug lobby, ousted
The generic drug industry’s lobbying group, the Association for Accessible Medicines, fired its president Dan…
STAT+: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill
Gilead Sciences won a key round in its battle with the U.S. government over allegations…
STAT+: With early data and a possible advantage, Amgen enters the obesity drug race
Amgen released detailed data on Thursday suggesting an early-stage drug can induce significant weight loss…
STAT+: Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
At a time when many Americans are clamoring for more transparency into prescription drug pricing,…
STAT+: Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
SAN FRANCISCO — The failure of a once-promising Alzheimer’s disease medicine from Roche appears to…
STAT+: Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi
Amgen, Janssen, and Sanofi are in talks to acquire Horizon Therapeutics, the Irish drugmaker confirmed…
STAT+: PhRMA, once invincible in Washington, has lost its edge
WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics,…
STAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
A hotly contested provision of a federal law designed to speed copycat drugs to market…
Opinion: Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage
Eisai’s announcement that lecanemab, its antibody drug for Alzheimer’s disease that targets the buildup of…
STAT+: Former Merck CEO: Democracy and the drug industry are both in danger
Ken Frazier, the former chief executive of Merck, has been the preeminent pharmaceutical CEO of…
STAT+: GSK to withdraw blood cancer drug from U.S. market following confirmatory study setback
British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep…
STAT+: Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs…
mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19…
Watch: This small-town pharmacy may be a model for more affordable drugs
STAUNTON, Va. — Honest Rx operates like any other pharmacy in the United States —…
STAT+: Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade
Amid ongoing concerns over the use of medically important antibiotics given to food-producing livestock and…
Opinion: STAT+: Removing barriers to biosimilar adoption in the United States
Biosimilars, a much-lauded approach to reducing drug costs in the United States, are still underused…
Opinion: The conundrum of biopharma investing: low rewards and high risks — but a big social benefit
Over the last decade, investors in biotech and pharmaceutical companies have been taking risks that…
The scientist behind Pfizer’s Covid vaccine says a flu pandemic is only a matter of time
BOSTON — Even after leading the charge combating the worst pandemic in a century, vaccine…
After decades of setbacks, scientists make strides toward the holy grail of male birth control
The headlines spelled the end of a short-lived scientific hope: “Male birth control study nixed…
STAT+: Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price…
STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall
For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps…
‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process
As the Covid-19 pandemic spread across the world two years ago, one of India’s leading…
STAT+: Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.
And so, another working week will soon draw to a close. Not a moment too…
STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices
Changing the way cancer drugs are priced in the U.S. is apparently even harder than…
STAT+: U.S. Supreme Court gives Amgen a boost by agreeing to review a closely watched patent case
In a boost for Amgen, the U.S. Supreme Court on Friday agreed to hear a…
STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
A leaked draft version of a trade agreement being negotiated between the United Kingdom and…
Opinion: Biopharma innovation needs to harness lessons learned from Covid-19
The pandemic is a prime case study of what can be accomplished when science delivers….
STAT+: Pharmalittle: FDA advisers vote down pediatric brain cancer drug; AbbVie drops out of psoriasis partnership
Good morning, and welcome to a spooky edition of Pharmalittle. It’s Jason Mast here, filling…
STAT+: Pharmalittle: Italy probes Pfizer over profit transfers; FDA postpones meeting for OTC birth control pill
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Q&A: A health justice lawyer and new MacArthur ‘genius’ on pharma’s patent games
Priti Krishtel has had it with the patent tricks up pharma’s sleeves. The co-executive director…
STAT+: Merck fined $39 million by Spain’s antitrust regulator for ‘serious’ violation
The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor…
STAT+: Dozens of institutional investors urge drugmakers to link executive compensation to access to medicines
Three dozen institutional investors are urging the boards at several of the world’s largest pharmaceutical…
BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market
What happens when approved drugs turn out not to work? Is it OK to make…
STAT+: Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries
Amid a push to widen access to medicines to poor countries, Novartis has reached an…
STAT+: How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’
After years of stops and starts, a law was finally passed in Congress this summer…
Opinion: What the Makena vote means about accelerated approval, trust, and the FDA
On Wednesday, the FDA advisory committee that oversees obstetrics, reproductive, and urologic drugs voted 14-1…
STAT+: FDA panel votes that a controversial premature birth medication should be withdrawn
After an extraordinary three-day hearing, an expert panel of advisers to the U.S. Food and…
STAT+: How many? A new analysis finds 1.3 million American adults rationed insulin due to cost
Amid ongoing controversy over the cost of insulin, a new analysis finds that approximately 1.3…
STAT+: Despite its threats, PhRMA is still supporting Democrats who voted for Medicare negotiation
Drugmakers’ powerhouse lobby did not exactly make good on its early August threat to hold…
STAT+: Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money
Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No…
STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug
South Korea’s anti-trust regulator has fined AstraZeneca and a local generic drugmaker a total of…
Opinion: Why the U.S. needs a public benefit biopharma industry
The biopharma industry is failing Americans, economically and medically. U.S. biotechnology and pharmaceutical companies, like…
STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients
The U.S. Food and Drug Administration and a trade group that represents large compound pharmacies…
.jpg)
STAT+: As small-town telepharmacies struggle to stay open, national chains eye an opportunity
In February 2019, the town of Albion, Ind. — population 2,500 — welcomed its first…
STAT+: European Commission says preliminary findings indicate Teva violated antitrust rules
After three years of probing, the European Commission has reached a preliminary decision that Teva…
STAT+: Merck touts positive results on key drug from $11.5 billion Acceleron merger
Merck said Monday the key drug from its $11.5 billion purchase of the biotech Acceleron…
After tough period for lobby, BIO chief Michelle McMurry-Heath goes on leave
WASHINGTON — Michelle McMurry-Heath, one of the most prominent faces of the drug industry in Washington,…